Yuhan Corporation wins Australia patent for anti-ulerant

Published: 2003-11-25 06:57:00

Updated: 2003-11-25 06:57:00

Yuhan Corporation announced recently that it won a patent from Australia for its novel pyrimidine derivative, known as derivatives of YH1885 (Revanex). It is a reversible proton pump inhibitor which is better effective in inhibiting the secretion of gastric juice than the conventional drugs.

T...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK